Siponimod Fumarate and Zyvox (Linezolid Suspension)

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer information for this interaction is not currently available.MONITOR CLOSELY: Coadministration of siponimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of unintended additive immunosuppressive effects. Siponimod causes reversible sequestration of lymphocytes in lymphoid tissues. When administered daily, siponimod produces a dose-dependent reduction in peripheral lymphocyte count to 20% to 30% of baseline values, which may increase the risk of infections. Life-threatening and rare fatal infections have occurred in association with siponimod. Decreased lymphocyte counts persist during chronic daily dosing and generally return to normal within 10 days after stopping the medication. Pharmacodynamic effects, such as decreased peripheral lymphocytes, may persist for 3 to 4 weeks after the last dose, and as a result, use of immunosuppressants during this time may also lead to additive immune effects. MANAGEMENT: The safety and efficacy of siponimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated. Caution is advised during coadministration and for 3 to 4 weeks after the last dose of siponimod. When switching from drugs with prolonged immune effects to siponimod, the half-life and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects while at the same time minimizing risk of disease reactivation. References "Product Information. Mayzent (siponimod)." Novartis Pharmaceuticals, East Hanover, NJ.

MONITOR CLOSELY: Coadministration of siponimod with antineoplastic, immunosuppressive, or other immune-modulating therapies may increase the risk of unintended additive immunosuppressive effects. Siponimod causes reversible sequestration of lymphocytes in lymphoid tissues. When administered daily, siponimod produces a dose-dependent reduction in peripheral lymphocyte count to 20% to 30% of baseline values, which may increase the risk of infections. Life-threatening and rare fatal infections have occurred in association with siponimod. Decreased lymphocyte counts persist during chronic daily dosing and generally return to normal within 10 days after stopping the medication. Pharmacodynamic effects, such as decreased peripheral lymphocytes, may persist for 3 to 4 weeks after the last dose, and as a result, use of immunosuppressants during this time may also lead to additive immune effects.

MANAGEMENT: The safety and efficacy of siponimod in combination with antineoplastic, immunosuppressive, or immune-modulating agents have not been evaluated. Caution is advised during coadministration and for 3 to 4 weeks after the last dose of siponimod. When switching from drugs with prolonged immune effects to siponimod, the half-life and mode of action of these drugs must be considered to avoid unintended additive immunosuppressive effects while at the same time minimizing risk of disease reactivation.

Siponimod Fumarate

Generic Name: siponimod

Brand name: Mayzent, Mayzent Starter Pack

Synonyms: Siponimod

What is Siponimod Fumarate?

Zyvox (Linezolid Suspension)

Generic Name: linezolid

Brand name: Zyvox

Synonyms: Zyvox

What is Zyvox (Linezolid Suspension)?